Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 11/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | PANK3 | Q9H999 | 7/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14924078 | 0.76 | OGA (0.50) | OGAACACBPANK3 | |
| SCHEMBL25736474 | 0.76 | ESR1 (0.37) | — | |
| SCHEMBL21453700 | 0.76 | ESR1 (0.38) | — | |
| SCHEMBL21125286 | 0.74 | NPC1 (0.36) | — | |
| SCHEMBL21125708 | 0.74 | NPC1 (0.36) | — | |
| SCHEMBL20046806 | 0.73 | OGA (0.42) | OGAPANK3 | |
| SCHEMBL20443650 | 0.72 | PANK3 (0.42) | OGAACACBPANK3 | |
| SCHEMBL10127337 | 0.72 | HTR3A (0.49) | OGAPANK3 | |
| SCHEMBL14239245 | 0.71 | MEN1 (0.48) | OGA | |
| SCHEMBL14349207 | 0.71 | PANK3 (0.46) | OGAACACBPANK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171470-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-02-11 | — | — | US | disclosed |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200155690-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | OGA 1276/4885ACACB 1442/4885PANK3 3113/4885 |
| US-20210171470-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | OGA 1276/4885ACACB 1442/4885PANK3 3113/4885 |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | OGA 1276/4885ACACB 1442/4885PANK3 3113/4885 |
| US-20200155690-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | OGA 1944/4885ACACB 2983/4885PANK3 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.